Novartis eyes vaccines with Protez purchase

Novartis is shelling out $400 million for antibiotics developer Protez Pharmaceuticals. Protez gets for $100 million up front and up to $300 million more if Protez's new broad-spectrum antibiotic is a success. The antibiotic, PZ-601, is in Phase II development and aims to treat multi-drug resistant bugs such as methicillin-resistant staphylococcus aureus (MRSA), which causes over 100,000 deaths in the U.S. and Europe annually.

The company has also been placing greater strategic emphasis on vaccine development, announcing today that it will start an anti-ulcer vaccine trial before year-end. The vaccine, which is in Phase I trials, will attempt to prevent recipients from acquiring Helicobacter pylori, a bug responsible for stomach ulcers. Novartis also has a candidate vaccine for Group B Streptococcus in Phase I trials and another for Group A Streptococcus slated to enter Phase I trials in 2010, along with a pneumococcal vaccine. Vaccines against meningococcal infections are in late stage development as well.

"The addition of Protez and its pipeline, including PZ-601, to our existing initiatives will further strengthen our position in the specialty field of hospital infections while helping to address the public health challenges of increasing bacterial resistance and high mortality rates," said Novartis' Joe Jimenez.

- see Novartis' release
- read the report from Forbes

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.